Jeremy Gratt
Bayer Corporation
5 Papers
47 Citations
Jeremy Gratt is an academic researcher from Bayer Corporation. The author has contributed to research in topics: Internal medicine & Expanded access. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Fred Saad,Joan Carles,Silke Gillessen,Axel Heidenreich,Daniel Heinrich,Jeremy Gratt,Jeremy Levy,Kurt Miller,Sten Nilsson,Oana Petrenciuc,Marcello Tucci,Manfred P. Wirth,Judith Federhofer,Joe M. O'Sullivan +13 more
TL;DR: This study investigated safety and overall survival in radium-223 treated patients in an early access programme done after the ALSYMPCA study and before regulatory approval of radia-223, an international, prospective, interventional, open-label, single-arm, phase 3b study.
284
Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
Oliver Sartor,Nicholas J. Vogelzang,Christopher Sweeney,Daniel Celestino Fernandez,Fabio Almeida,Andrei Iagaru,Alan Brown,Matthew R. Smith,Manish Agrawal,Adam P. Dicker,Jorge A. Garcia,Jose Lutzky,Yu-Ning Wong,Oana Petrenciuc,Jeremy Gratt,Neal D. Shore,Michael J. Morris,Michael J. Morris +17 more
TL;DR: Radium-223 was well tolerated, with no new safety concerns; safety was maintained with abiraterone or enzalutamide; and median overall survival appeared longer when radium- 223 was used earlier in patients with less prior treatment.
73
Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients.
Fred Saad,Joan Carles,Silke Gillessen,Daniel Heinrich,Jeremy Gratt,Kurt Miller,Sten Nilsson,Joe M. O'Sullivan,Marcello Tucci,Manfred P. Wirth,Axel Heidenreich +10 more
TL;DR: In this article, the pivotal ALSYMPCA study reported improved overall survival (OS) in bone symptomatic mCRPC patients (pts) treated with radium-223 (Ra-223) vs placebo (median 14.9 vs 11.6 months).
22
Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting.
A. Oliver Sartor,Daniel Celestino Fernandez,Michael J. Morris,Andrei Iagaru,Alan Brown,Fabio Almeida,Christopher Sweeney,Matthew R. Smith,Adam P. Dicker,Yu-Ning Wong,Neal D. Shore,Jeremy Gratt,Oana Petrenciuc,Nicholas J. Vogelzang +13 more
TL;DR: Experiences with RA-223 in relationship to Abi and Enza are provided to monitor acute and long-term safety of Ra-223 CL2 and to assess safety and overall survival in pts with prior and concurrent Abi or Enza.
19
Ra-223 experience in pretreated patients: EAP setting.
A. Oliver Sartor,Daniel Celestino Fernandez,Michael J. Morris,Andrei Iagaru,Alan Brown,Fabio Almeida,Christopher Sweeney,Matthew R. Smith,Adam P. Dicker,Yu-Ning Wong,Neal D. Shore,Jeremy Gratt,Oana Petrenciuc,Joseph Germino,Nicholas J. Vogelzang +14 more
TL;DR: The baseline characteristics and number of cycles administered in pts naive to, with prior use of either/or, and abi + enza were examined in relation to prior therapy with abiraterone (abi) and/or enzalutamide (enza).
14